Is DOTS-plus a feasible and cost-effective strategy?
Garner
Paul
P
Liverpool School of Tropical Medicine, Liverpool, United Kingdom. pgarner@liv.ac.uk
Alejandria
Marissa
M
Lansang
Mary Ann
MA
D003362:Cost-Benefit Analysis; D023801:Directly Observed Therapy / Q000191:economics*; D005240:Feasibility Studies; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000191:economics* / Q000453:epidemiology / Q000628:therapy; D014944:World Health Organization